S
Sorintellis
$781K raised4 employees
AI decision intelligence for clinical drug development
Trained in pharmacy, with an MBA. He founded Sorintellis in Montréal in 2022 to apply AI to clinical drug development and pharmaceutical portfolio decisions.
- BackgroundPharmacy and management. Dealroom tags his background as technical, business, medical and entrepreneurship.
- PatentsInventor on both Sorintellis patent families: six filings in the US, Europe, Canada, China and under the PCT.
- ResearchCo-author of the March 2026 arXiv paper on predicting clinical trial success with TrialsBank (13,700 trials).
- PartnershipsNamed for Sorintellis in the July 2026 research partnership with HEC Montréal, supported by IVADO and Mitacs.
- Capital raised$781K across seven rounds since 2022, mostly grants: Prompt, CQDM, IVADO, Mitacs and the Government of Quebec.
Holds a PharmD and an MSc. She is the lead author of the company’s 2026 research paper on TrialsBank.
- ResearchLead author of the March 2026 arXiv paper. It reports F1 scores of 0.93, 0.92 and 0.91 for predicting operational success in Phase I, II and III trials.
- PatentsCo-inventor on the 2024 international application WO2025129360A1.
- PartnershipsNamed in the HEC Montréal partnership announcement of July 2026.
About Sorintellis
Sorintellis is a Montreal-based life sciences technology company that builds AI-powered decision intelligence for clinical drug development and pharmaceutical portfolio management. Its aim is to help drug developers design, optimize, prioritize and execute development programs with more precision and predictability. The foundation is TrialsBank, a proprietary, expert-curated clinical trials database that links scientific, clinical, operational, regulatory, commercial and financial data into a structured, AI-ready layer. On top of it, the VALOQIS platform uses machine learning, predictive analytics and causal AI to support clinical trial protocol design, trial risk assessment, probability of technical and regulatory success (PTRS) prediction, drug asset valuation, R&D portfolio prioritization and capital allocation. Its AI methods for clinical trial success analysis and portfolio decision support are covered by pending patent applications under the PCT and in the US, Europe, Canada and China. Customers include pharmaceutical and biotechnology companies, contract research organizations (CROs), clinical research sites and life sciences investors, who use its insights for go/no-go decisions and due diligence. The platform is offered to businesses as subscription software.
Source: Dealroom company dataSorintellis in the Montréal ecosystem
The Sorintellis office with the city's hot startups, its neighbours, its first investor and the universities around it. Hover or tap a pin.
Hot startups
- XNRGY Climate Systems: founded 2017 · Signal 91 · XNRGY offers large dedicated outside air systems and custom air handlers incorporating energy recovery technologies…
- Haply: $15.3M raised · founded 2017 · Signal 90 · Technology that touches lives
- Eli: $17.8M raised · founded 2019 · Signal 90 · Enables women to take control of their health across their reproductive lives, by providing them with their daily…
- Reaction Dynamics: $27.4M raised · founded 2016 · Signal 89 · Hybrid rocket propulsion for responsive small satellite launches
- Maket: $2.5M raised · founded 2019 · Signal 86 · Maket uses its Architectural Brain to design smarter floor plans—automatically optimized, editable, and ready to…
- Gallea: $1.2M raised · founded 2016 · Signal 84 · Buy Art Online, Art Gallery and Exhibitions
- Mecademic: $15.3M raised · founded 2013 · Signal 82 · Mecademic designs and manufactures the most compact and precise six-axis industrial robot
- Unito: $32.9M raised · founded 2015 · Signal 82 · Automatically synchronizes projects, tasks and conversations between different work management tools
- Axya: $16.9M raised · founded 2019 · Signal 82 · Supply management software for your subcontracting
- ChillSkyn: $1.9M raised · founded 2022 · Signal 81 · Nanostructured coatings for zero-energy radiative cooling solutions
- One Silicon Chip Photonics: $3.5M raised · founded 2015 · Signal 81 · Photonics Integrated Circuits Motion Sensor Company
- Aerial Technologies: $7.4M raised · founded 2015 · Signal 81 · Leverages AI and existing wireless infrastructure to create Sensing Intelligence that enables smarter applications
Nearby companies
- Paper: $390.1M raised · founded 2014 · Signal 63 · 0.9 km away · Connecting learning community with the only Educational Support System designed to augment teaching and promote learning
- Nesto: $222.6M raised · founded 2018 · Signal 94 · 0.9 km away · AI-powered digital mortgage and lending technology platform.
- WorkJam: $161.7M raised · founded 2014 · Signal 66 · 0.5 km away · The world leader in the digital frontline workplace, revolutionizing how HQs & their frontline work together
- Dcbel: $145M raised · founded 2015 · Signal 84 · 0.8 km away · Next-generation digital energy products that enable the transition to a customer-centric, distributed energy future
- StreamingFast: $63.5M raised · founded 2018 · Signal 67 · 0.1 km away · Protocol infrastructure company that provides a massively scalable architecture for streaming blockchain data
- Planned: $49.7M raised · founded 2017 · Signal 89 · 1.1 km away · A platform that is redefining the way in-person events are planned
- MEDFAR: $40.3M raised · founded 2010 · Signal 69 · 0.7 km away · Leveraging healthcare experience, research, and passion with the latest cloud-based technology to offer medical…
- Ability Biologics: $18M raised · founded 2023 · Signal 80 · 0.3 km away · Developing innovative targeted immuno therapeutics to addressing unmet medical needs for cancer and autoimmune diseases
- Mechasys: $17.8M raised · founded 2018 · Signal 61 · 0.7 km away · Displays construction plans in real scale directly on construction sites
Key investor
- Prompt: 1200 McGill College Avenue · Quebec’s funding consortium for AI and digital innovation projects. It put CA$232,795 into a CA$464,591 Sorintellis and Vantage BioTrials project in 2022.
Universities
- McGill University: Downtown campus · 2,865 founders and 42 unicorns among its alumni companies on Dealroom.
- Université de Montréal: Roger-Gaudry building · 671 founders, 6 unicorns. Biostatistics professor Mireille E. Schnitzer co-wrote Sorintellis’s 2026 TrialsBank paper.
- HEC Montréal: Côte-Sainte-Catherine campus · Research partner since July 2026, building an AI valuation framework for drug assets on TrialsBank. 101 founders on Dealroom.
- Concordia University: Sir George Williams campus · 1,468 founders and 4 unicorns among its alumni companies.
- Polytechnique Montréal: Engineering school · 202 founders and 3 unicorns among its alumni companies.
- ÉTS: École de technologie supérieure · 284 founders and 2 unicorns among its alumni companies.
- UQAM: Université du Québec à Montréal · 55 founders among its alumni companies.
Also hot in Montréal
- Coral: $5.9M raised · founded 2023 · Signal 93 · Comprehensive menopause support program offering personalized treatment paths and community engagement for symptom…
- Saris AI: $28.8M raised · founded 2023 · Signal 92 · AI-driven negotiation and workflow agents reducing costs and boosting output for financial services
- Archie App: $1M raised · founded 2016 · Signal 89 · A seamless solution for coworking spaces and flexible offices
- FrontlineIQ: $3.3M raised · founded 2024 · Signal 88 · AI sales coaching platform for frontline teams
- WorkAxle: $2.8M raised · founded 2017 · Signal 87 · WorkAxle is the leading employee management platform for shift workers. WorkAxle saves business owners and their…
- Embrace Software: $10M raised · founded 2019 · Signal 87 · Embrace acquires and invests in niche, industry-specific software companies, providing them with capital and expertise…
- Oligon Therapeutics: $14M raised · founded 2021 · Signal 86 · Multimodal RNA therapeutics silencing multiple disease targets
- Exterra Technologies: $14.7M raised · founded 2021 · Signal 86 · Rock Solid Carbon Sequestration Solutions
- AssistIQ: $13.3M raised · founded 2021 · Signal 86 · AssistIQ empowers hospitals, payers and partners with actionable insights to
- Paraito: $1.9M raised · founded 2025 · Signal 86 · AI-powered platform automating real estate title searches.
Source: Dealroom, 12 November 2026. Office and campus locations from OpenStreetMap. Prompt funding from Prompt’s funded-projects page.
News
Sorintellis and its peers
Sorintellis is one of 7 companies on Dealroom's AI for clinical trials map that work on probability of success and portfolio decisions. It has raised the least of the 4 that disclose funding.
-
IntelligenciaFounded 2017 · New York City
$12.6M
-
PheironFounded 2023 · Berlin
$4.2M
-
PharosynFounded 2025 · London
$3M
-
SorintellisFounded 2022 · Montreal
$781K
-
CaladanAIFounded 2026 · Portland
Not disclosed
-
MyelinFounded 2026 · New York City
Not disclosed
-
PharmitivFounded 2026 · Jaipur
Not disclosed
The whole AI for clinical trials map: 61 companies in 5 segments
- 7Probability of success and portfolio decisions$20.6M raised
- 15Trial design and simulation$375.7M raised
- 11Patient recruitment and site matching$263.9M raised
- 18Trial operations and clinical data$994.9M raised
- 10Real-world data and evidence$680.3M raised
Open the AI for clinical trials map →Dealroom AI for clinical trials map, updated 2026-11-12. Total disclosed funding per company.
Market map
On the AI for clinical trials map, Sorintellis is grouped with companies that predict drug programme success and support portfolio decisions.
Closest companiesInvestors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Prompt
IVADO
Mitacs
CQDM
Government of Quebec
Patents
Two patent families, both pending. None has been granted yet.
AI decision support for pharmaceutical portfolio management
Predicts whether a clinical trial will succeed from trial, regulatory, economic, drug and company data. The US application had a first rejection in April 2026 and is still pending.
Priority date 23 Jun 2022 (US 63/366,875) · Inventors: Emmanuel Piffo, Diana Avramioti, Jordan Gierschendorf, Camelia Raymond
| Filing | Number | Published | Status |
|---|---|---|---|
| International patent application (PCT)Holds the filing date open for patents in more than 150 countries | PCT/CA2023/050878WO2023245301A1 | 28 Dec 2023 | Moved to the national filings below |
| US patent applicationProtection in the United States | 18/878,329US20250384454A1 | 18 Dec 2025 | Pending |
| European patent applicationProtection across the European Patent Office’s member states | 23825736.4EP4544474A1 | 30 Apr 2025 | Pending |
| Canadian patent applicationProtection in Canada | 3,260,438CA3260438A1 | 28 Dec 2023 | Pending |
| Chinese patent applicationProtection in China | 202380055056.4CN119585753A | 7 Mar 2025 | Pending |
Predicting clinical trial success with a two-level model
A two-step model: it first predicts trial risks such as slow recruitment, then uses them to estimate the chance of success and explain it.
Priority date 22 Dec 2023 (US 63/614,374) · Inventors: Emmanuel Piffo, Iness Halimi, Diana Avramioti, Jordan Gierschendorf, Camelia Raymond, Martin Sotir
| Filing | Number | Published | Status |
|---|---|---|---|
| International patent application (PCT)Holds the filing date open for patents in more than 150 countries | PCT/CA2024/051726WO2025129360A1 | 26 Jun 2025 | Pending |
Source: Google Patents, USPTO and WIPO PATENTSCOPE records, checked 12 November 2026. Status is as reported by Google Patents.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sorintellis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Updated daily